Aeov­ian Phar­ma­ceu­ti­cals brings in $37 mil­lion in mTOR play

6 years ago
Financing
Startups

Re­gen­eron dou­bles down on part­ner Adicet's gam­ma delta T cell tech in $80M fi­nanc­ing

6 years ago
Financing
Cell/Gene Tx

Piv­otal fail­ure trig­gers job cuts at San Diego-based Toca­gen

6 years ago
People

Icosavax nabs $51M as syn­thet­ic virus heads to­ward clin­ic

6 years ago
R&D

San Fran­cis­co biotech has its heart in heart fail­ure — and $92M in the bank

6 years ago
Startups
Cell/Gene Tx

ARC-T? Al­ter­na­tive CAR-T start­up bags $85M for clin­i­cal quest to redi­rect 'blind hunter' T cells

6 years ago
Startups
Cell/Gene Tx

ADC Ther­a­peu­tics is­n't go­ing pub­lic in the US af­ter all, while three oth­er biotech IPOs bring in $319M

6 years ago
Financing

In an un­usu­al move, ICER re­scinds draft re­port on JAK drugs for rheuma­toid arthri­tis to re­vise its mod­el­ing ap­proach

6 years ago
Pharma
FDA+

When can RWE trans­late in­to cred­i­ble ev­i­dence? EMA of­fi­cials dis­cuss

6 years ago
FDA+

Vivek Ra­maswamy en­gi­neers new deal with RTW to take Pe­te Salz­man­n's Im­muno­vant pub­lic

6 years ago
Deals

More bad news for Sarep­ta; No­var­tis, Mi­crosoft join forces in AI pact

6 years ago
News Briefing

As its on­col­o­gy ef­fort gath­ers steam, As­traZeneca sheds an­oth­er lega­cy drug

6 years ago
Deals

Neoanti­gen play­er PACT Phar­ma woos Tim Moore from Kite to run tech­ni­cal ops

6 years ago
People
Cell/Gene Tx

J&J set­tles Ohio opi­oid case for $20.4M, avoids loom­ing tri­al

6 years ago
Pharma

As de­vel­op­ers work on crack­ing KRAS, Ger­many's Boehringer has qui­et­ly be­gun test­ing its pan-KRAS drug in hu­mans

6 years ago
R&D

No­var­tis stacks more pos­i­tive PhI­II da­ta on Cosen­tyx fran­chise — eye­ing ap­proval in non-ra­di­ograph­ic ax­i­al ...

6 years ago
R&D
Pharma

Trou­bled poop-test­ing start­up uBio­me an­nounces plans for liq­ui­da­tion

6 years ago
R&D

The time is now: John Cox as­sumes CEO post at Flag­ship-backed Torque, steer­ing cell ther­a­py to clin­i­cal tri­als

6 years ago
People
Cell/Gene Tx

Trump will pick Stephen Hahn as his next FDA com­mis­sion­er — re­ports

6 years ago
People
FDA+

For­mer Akcea pres­i­dent makes the leap to CEO seat at Avid­i­ty Bio­sciences; Astel­las in­vests $12.5M in­to two in­cu­ba­tors

6 years ago
News Briefing

New norm? Three biotechs pen­cil in $100M IPOs

6 years ago
Financing

For­mer FDA chief Califf is set to work full time for Al­pha­bet

6 years ago
People
FDA+

Chris Collins set to change his plea on biotech in­sid­er trad­ing scan­dal, ex­it­ing House seat

6 years ago
People

Ver­tex taps a team play­er to take over as CMO dur­ing a big tran­si­tion at the top

6 years ago
R&D
First page Previous page 893894895896897898899 Next page Last page
A service from the Financial Times